CellCentric out-licenses epigenetic discovery programme

Tuesday 23 February 2010

In a boost for the emerging field of epigenetics, privately-owned CellCentric Ltd of Cambridge, UK has negotiated access to one of its cancer discovery programmes to Takeda Pharmaceutical Company Ltd. The deal is valued at about $200 million.

 

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom